Literature DB >> 11243712

The role of endothelins and their receptors in heart failure.

D Giannessi1, S Del Ry, R L Vitale.   

Abstract

Endothelin (ET) is a peptide composed of 21 amino acids, derived from a larger precursor, the big-endothelin, by action of the endothelin-converting enzyme (ECE) family; three isoforms of endothelin, named ET-1, ET-2 and ET-3, have been identified. Endothelin-1 is generated mainly by vascular endothelial cells and exerts various important biological actions, mediated by two receptor subtypes, ET-A and ET-B, belonging to the G protein-coupled family that have been identified in various human tissues such as the cardiac tissue. Endothelin-1 is a potent vasoconstrictive agent, has inotropic and mitogenic actions, modulates salt and water homeostasis and plays an important role in the maintenance of vascular tone and blood pressure in healthy subjects. Endothelin-1, as well as ET-A and ECE-1, also has an important role in cardiovascular development, as observed by the variety of abnormalities related to neural crest-derived tissues in mouse embryos deficient of a member of the ET-1/ECE-1/ET-A pathway. Various evidence indicates that endogenous endothelin-1 may contribute to the pathophysiology of conditions associated with sustained vasoconstriction, such as heart failure. In heart failure, elevated circulating levels of both endothelin-1 and big-endothelin-1 are observed; in failing hearts an activation of the endothelin system is found: tissue level of ET-1 is increased with respect to non-failing hearts as well as receptor density, due mainly to an upregulation of the ET-A subtype, the prevalent receptor subclass in cardiac tissue. Finally, studies in both humans and animal models of cardiovascular disease show that inhibition of the endothelin function (anti-endothelin strategy) is associated with an improvement of haemodynamic conditions; these observations indicate that endothelin receptor antagonists or endothelin-converting enzyme inhibitors may constitute a novel and potentially important class of agents for the treatment of this disease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243712     DOI: 10.1006/phrs.2000.0758

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  19 in total

1.  Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

Authors:  Jasper Dingemanse; Dieter Schaarschmidt; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Cytokine G-protein signaling crosstalk in cardiomyocytes: attenuation of Jak-STAT activation by endothelin-1.

Authors:  George W Booz; Jonathan N E Day; Robert Speth; Kenneth M Baker
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

Review 3.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

4.  Phorbol ester and endothelin-1 alter functional expression of Na+/Ca2+ exchange, K+, and Ca2+ currents in cultured neonatal rat myocytes.

Authors:  José L Puglisi; Weilong Yuan; Valeriy Timofeyev; Richard E Myers; Nipavan Chiamvimonvat; Allen M Samarel; Donald M Bers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-03       Impact factor: 4.733

Review 5.  Endothelins and their receptors in cancer: identification of therapeutic targets.

Authors:  Rong Wang; Roderick H Dashwood
Journal:  Pharmacol Res       Date:  2011-01-18       Impact factor: 7.658

6.  Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.

Authors:  Matthew R G Taylor; Dobromir Slavov; Kurt Humphrey; Lan Zhao; Jennifer Cockroft; Xiao Zhu; Philip Lavori; Michael R Bristow; Luisa Mestroni; Laura C Lazzeroni
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

7.  Influence of endothelin 1 receptor inhibition on functional, structural and molecular changes in the rat heart after irradiation.

Authors:  Marjan Boerma; Junru Wang; Ashwini Kulkarni; Kerrey A Roberto; Xiaohua Qiu; Richard H Kennedy; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2008-09       Impact factor: 2.841

8.  ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats.

Authors:  David B Murray; Ronald McMillan; Gregory L Brower; Joseph S Janicki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

9.  Cell-type specific interaction of endothelin and the nitric oxide system: pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice.

Authors:  Torsten Slowinski; Philipp Kalk; Maren Christian; Fred Schmager; Katharina Relle; Michael Godes; Heiko Funke-Kaiser; Hans-H Neumayer; Christian Bauer; Franz Theuring; Berthold Hocher
Journal:  J Physiol       Date:  2007-03-29       Impact factor: 5.182

10.  Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics.

Authors:  John M Toole; John S Ikonomidis; Wilson Y Szeto; James L Zellner; John Mulcahy; Rachael L Deardorff; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2010-01-13       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.